Raxibacumab

Raxibacumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	Protective antigen of anthrax toxin
Identifiers
CAS Number	565451-13-0
ATC code	none
Chemical data
Formula	C6320H9794N1702O1998S42
Molar mass	142.93 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proved in rabbits and monkeys.^[1] As of September 2009^[update], its safety in humans is being evaluated.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40x30px

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

↑ Migone, TS; Subramanian, GM; Zhong, J; Healey, LM; Corey, A; Devalaraja, M; Lo, L; Ullrich, S; Zimmerman, J (2009). "Raxibacumab for the treatment of inhalational anthrax". The New England journal of medicine. 361 (2): 135–44. doi:10.1056/NEJMoa0810603. PMID 19587338.
↑ ClinicalTrials.gov

[1] Migone, TS; Subramanian, GM; Zhong, J; Healey, LM; Corey, A; Devalaraja, M; Lo, L; Ullrich, S; Zimmerman, J (2009). "Raxibacumab for the treatment of inhalational anthrax". The New England journal of medicine. 361 (2): 135–44. doi:10.1056/NEJMoa0810603. PMID 19587338.

[2] ClinicalTrials.gov

[1]

[2]

v t e Human monoclonal antibodies ("-u-")
"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Fresolimumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab, Zanolimumab
"-kinu-" (interleukin as target)	Briakinumab, Canakinumab, Ustekinumab
"-tumu-"/"-tu-" (tumor)	Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Necitumumab, Ofatumumab, Olaratumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab
"-osu-" (bone)	Denosumab
"-mulu-" (musculoskeletal)	Stamulumab^†
"-fungu-" (fungal)	Efungumab
"-viru-" (viral)	Exbivirumab, Foravirumab, Libivirumab, Rafivirumab, Regavirumab, Sevirumab, Tuvirumab
"-bacu-" (bacterial)	Nebacumab, Panobacumab, Raxibacumab
"-ciru-" (cardiovascular)	Ramucirumab
"-neru-" (neurologic)	Gantenerumab
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Raxibacumab

References

Navigation menu

Views

Personal tools

Navigation

Search

Tools

adverts